A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia

Live births, natural losses and elective terminations with Down syndrome in Massachusetts

(2016) Gert de Graaf et al.   GENETICS IN MEDICINE

Vitamin E in aging persons with Down syndrome

(2016) Mary Sano et al.   NEUROLOGY

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome

(2015) Michael S. Rafii et al.   Frontiers in Behavioral Neuroscience

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

(2012) Benjamin L. Handen et al.   Alzheimers & Dementia

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial

(2012) R Boada et al.   Translational Psychiatry

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Development and validation of the Arizona Cognitive Test Battery for Down syndrome

(2010) Jamie O. Edgin et al.   Journal of Neurodevelopmental Disorders

Down Syndrome: From Understanding the Neurobiology to Therapy

(2010) K. Gardiner et al.   JOURNAL OF NEUROSCIENCE

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

(2010) Ira T Lott et al.   LANCET NEUROLOGY

Cognition assessment in paediatric clinical trials

(2007) C EDGAR   DRUG DISCOVERY TODAY